Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: billkirn who wrote (589)	6/27/1998 9:16:00 AM
From: jon wilson	Read Replies (1) \| Respond to of 1510

Any guess as to where we will be next week ?

To: billkirn who wrote (589)	6/27/1998 7:08:00 PM
From: AHM	Respond to of 1510

Don't count on it coming down another 2 3/4 points (to 14) from Friday's closing bid of 16 3/4. Dr. Valentine addresses AIDS symposium July 3rd. Immune Response IMNR has conducted a 2,500 patient test utilizing REMUNE, a patented drug to improve the body's immune system to fight AIDS based on patents assigned to the company by its co-founder, Dr. Jonas Salk. Quoting from an earlier 10-K: "The Principal Investigator of this trial, Dr. Fred Valentine, is Professor of Medicine at New York University Medical Center and the former Chairman of the Food and Drug Administration's Antiviral Drugs Advisory Committee. The trial will be conducted at New York University Medical Center, Johns Hopkins University, Finch University of Health Sciences at Chicago Medical School, Institute of Human Virology - University of Maryland, North Shore University Hospital - New York University, University of California at Davis, University of Hawaii and Harvard University Medical School." This is not a lightweight! Further reference to this landmark study is in 6/21/98 New York Times magazine section (page 25 - 4th paragraph from the end). Since the company's web page imnr.com indicates that Dr. Valentine's appearance as a presenter at this conference is a "Late Breaker - July 3, 1998, 10:00 a.m. - Dr. Fred Valentine" it is safe to assume that he has something highly dramatic to present. Betting the farm on this one is not a bad bet! Latest information discloses that 35 institutional investors own 21.28% and insiders 12.44% of 22,869,000 shares outstanding. Assuming that institutional investors will hold on for a while, not too many shares for the public at large - it will, in my opinion, be highly volatile this coming week and a great celebratory wrap-up to the 4th of July weekend!

To: billkirn who wrote (589)	6/28/1998 11:49:00 PM
From: Manny Gugliuzza	Read Replies (1) \| Respond to of 1510

billkirn, when you expect that 14 will be seen again , what is your time frame on that? when IMNR broke out of the last trading range of single digits, trades were higher for 5 weeks in a row. although that was then and this is now. good fundamentals have been consistent but now they are strong and will control biotech thinking in this field. technicals are following with the 1st week thu the resistant area of 15 i expect this to become support. how soon the test will be i am not sure. i was a little worried at the opening on Fri. below the thurs. close. this gap could be a reversal but it did trade up to the close. short term stochastics 15-5-5-1 and the slower 13-7-7-1 have not confirmed a sell signal. the quicker 10K and 4D have, however the divergence is huge almost like it has bottomed. MACD still increasing even on Fri. trading. i had only 3-400,000 shares on the sell side friday, same 1/3 as thurs % the next few days will mark either a similar pattern like the rise on june 12th testing this gap area as i had expected(AGPH's purchase price) or complete the uptrend channel at 15.5-15.75 tomorrow,then 16.5 the next and up. that is on a daily 1$ scale chart. the weekly charts are better to look at and help to smooth out the rough edges. that has the uptrend very steep and us stepping out at 17 and rising 3.5 points next week. good luck to all. ar.